logo
Twitter
Discord
Email
logo
Metagenomi, Inc.

Metagenomi, Inc.

NASDAQ•MGX
CEO: Dr. Brian Charles Thomas Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2006-04-06
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Contact Information
5959 Horton Street, 7th Floor, EmeryVille, CA, 94608, United States
510-871-4880
www.metagenomi.co
Market Cap
$62.33M
P/E (TTM)
-0.7
38.2
Dividend Yield
--
52W High
$4.00
52W Low
$1.23
52W Range
16%
Rank39Top 39.1%
4.2
F-Score
Modified Piotroski Analysis
Based on 4-year fundamentals
Average • 4.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2022-2025

Financial Dashboard

Q3 2025 Data

Revenue

$8.66M-24.80%
4-Quarter Trend

EPS

-$0.55+7.84%
4-Quarter Trend

FCF

-$21.33M-23.39%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Collaboration Revenue Decreases Nine-month collaboration revenue $21.3M, down $21.4M, primarily due to Moderna Agreement termination recognized in 2024.
R&D Spending Reduced Nine-month Research and development expenses $72.9M, down $13.1M, reflecting reduced activity post-collaboration wind-down.
Sufficient Cash Runway Cash, cash equivalents, and marketable securities total $184.1M, funding operations for at least the next 12 months.
Key Executive Transition New CEO Jian Irish appointed effective November 6, 2025; Founder Brian Thomas resigned from CEO role.

Risk Factors

Significant Accumulated Deficit Accumulated deficit reached $(288.3M) as of September 30, 2025; substantial future losses expected indefinitely.
Pending Securities Litigation Class action lawsuit regarding Moderna collaboration remains pending; outcome uncertain, potentially causing material adverse effects.
Need Substantial Funding Operations require substantial additional capital to fund ongoing research and development activities; failure risks delays.
Novel Technology Hurdles Genome editing technology faces regulatory uncertainty and potential for adverse clinical trial outcomes or unexpected side effects.

Outlook

Advance MGX-001 Program Plan to submit IND/CTA for MGX-001 in Q4 2026, aiming to initiate clinical trials during 2027.
Ionis Candidate Nomination Expect to nominate a Wave 1 development candidate from Ionis collaboration targets during the 2025 calendar year.
Integrate New Leadership New CEO and CFO transitions underway; focus on maintaining continuity and executing strategic restructuring plans.
ATM Program Inactive No shares sold under the $75.0M ATM Sales Agreement as of September 30, 2025; flexibility remains.

Peer Comparison

Revenue (TTM)

Metagenomi, Inc.MGX
$30.91M
-43.9%
Zentalis Pharmaceuticals, Inc.ZNTL
$26.87M
-37.0%
Seer, Inc.SEER
$16.33M
+14.5%

Gross Margin (Latest Quarter)

Surrozen, Inc.SRZN
100.0%
+0.0pp
Opus Genetics, Inc.IRD
99.6%
-0.4pp
Metagenomi, Inc.MGX
84.7%
-15.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ARMP$233.00M-4.970.3%198.5%
ZNTL$213.86M-1.4-51.5%11.2%
SRZN$171.43M-2.0-4404.2%7.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-3.4%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 16, 2026
|
EPS:-$0.58
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $8.66M-24.8%
    |
    EPS: $-0.55+7.8%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 12, 2025|
    Revenue: $8.51M-57.5%
    |
    EPS: $-0.54+86.2%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 13, 2025|
    Revenue: $4.13M-63.0%
    |
    EPS: $-0.68+1.5%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 17, 2025|
    Revenue: $52.30M+16.8%
    |
    EPS: $-2.09-14.8%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 13, 2024|
    Revenue: $11.51M-6.9%
    |
    EPS: $-0.51-3.8%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 14, 2024|
    Revenue: $20.01M+76.5%
    |
    EPS: $-0.29-16.5%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 14, 2024|
    Revenue: $11.16M+28.9%
    |
    EPS: $-0.67+24.1%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 27, 2024|
    Revenue: $44.76M+160.2%
    |
    EPS: $-1.82-56.9%
    Beat